Allegro announces positive results of ex-US proof-of-concept trial with ALG-1007 for dry eye disease

Allegro announces positive results of ex-US proof-of-concept trial with ALG-1007 for dry eye disease

Source: 
Pharmaceutical Business Review
snippet: 

Allegro Ophthalmics, LLC, a privately held biopharmaceutical company focused on the development of novel anti-integrin therapies for the treatment of ocular diseases, today announced positive results of an ex-U.S. proof-of-concept clinical trial of the new investigational ALG-1007 topical drop drug candidate in patients with dry eye disease (DED).